Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

[1]  Yanpeng Xu,et al.  Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira® , 2020, The AAPS Journal.

[2]  Zhuoli Zhang,et al.  Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial , 2020, BioDrugs.

[3]  W. Liao,et al.  Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis , 2020, American Journal of Clinical Dermatology.

[4]  S. Simoens,et al.  The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases , 2020, Drugs.

[5]  V. Strand,et al.  Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents , 2019, BioDrugs.

[6]  Guideline for the diagnosis and treatment of psoriasis in China （2018 complete edition） , 2019, Chinese Journal of Dermatology.

[7]  Pantelis K. Vlachos,et al.  AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis , 2019, The British journal of dermatology.

[8]  Huji Xu,et al.  IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. , 2019, The Lancet Rheumatology.

[9]  L. Puig,et al.  Biosimilars for the treatment of psoriasis , 2019, Expert opinion on biological therapy.

[10]  G. Fanjiang,et al.  A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501 , 2019, Advances in Therapy.

[11]  He Gao,et al.  FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB , 2019, Poster Presentations.

[12]  Jian Wu,et al.  FRI0415 BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL , 2019, Spondyloarthritis – treatment.

[13]  T. Hickling,et al.  Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab , 2018, Clinical and experimental immunology.

[14]  A. Enk,et al.  Biosimilars in Dermatology – theory becomes reality , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15]  A. Menter,et al.  Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry , 2017, Dermatology and Therapy.

[16]  B. Strober,et al.  Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double‐blind, multicenter, phase III study , 2017, Journal of the American Academy of Dermatology.

[17]  G. Wang,et al.  Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  Carol F. Kirchhoff,et al.  Development of biosimilars. , 2016, Seminars in arthritis and rheumatism.

[19]  G. Goldenberg,et al.  Biologic safety in psoriasis: review of long-term safety data. , 2015, The Journal of clinical and aesthetic dermatology.

[20]  I. Olivieri,et al.  The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. , 2014, Autoimmunity reviews.

[21]  Yue Zhao,et al.  Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab , 2014, Patient preference and adherence.

[22]  Y. Liu,et al.  Prevalence of psoriasis in China: a population-based study in six cities. , 2012, European journal of dermatology : EJD.

[23]  H. Nakagawa,et al.  Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study , 2010, The Journal of dermatology.

[24]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[25]  Sung-Jan Lin,et al.  Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis. , 2015, Acta dermato-venereologica.

[26]  GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING BIOTECHNOLOGY-DERIVED PROTEINS AS ACTIVE SUBSTANCE: NON-CLINICAL AND CLINICAL ISSUES , 2011 .

[27]  English Only,et al.  GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) , 2009 .

[28]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[29]  I. Knezevic,et al.  [Biological standardization]. , 1972, Harefuah.